<code id='29A71AC032'></code><style id='29A71AC032'></style>
    • <acronym id='29A71AC032'></acronym>
      <center id='29A71AC032'><center id='29A71AC032'><tfoot id='29A71AC032'></tfoot></center><abbr id='29A71AC032'><dir id='29A71AC032'><tfoot id='29A71AC032'></tfoot><noframes id='29A71AC032'>

    • <optgroup id='29A71AC032'><strike id='29A71AC032'><sup id='29A71AC032'></sup></strike><code id='29A71AC032'></code></optgroup>
        1. <b id='29A71AC032'><label id='29A71AC032'><select id='29A71AC032'><dt id='29A71AC032'><span id='29A71AC032'></span></dt></select></label></b><u id='29A71AC032'></u>
          <i id='29A71AC032'><strike id='29A71AC032'><tt id='29A71AC032'><pre id='29A71AC032'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:6

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus